Manufacturers are investing in key recombinant vaccines and improving product pipelines, driving growth in the market.

CanSinoBIO’s vaccine is a recombinant viral vector vaccine, a class of vaccines that use a modified version of a different virus to deliver instructions to cells that trigger an immune response.

Convidecia is under clinical development by CanSino Biologics and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

The Ad5-EBOV vaccine developed in China relies on the recombinant replication-defective human adenovirus type-5 vector to induce immune responses and provide protection against the Ebola virus.

It is hard to overestimate the importance of antibodies in the frameworks of biotechnology and pharmaceutical industries.

Registration is open for faculty to attend the Westwood Lecture Series on Jan. 28. Suresh Mittal, Distinguished Professor of Virology in the College of Veterinary Medicine, will present ...

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral ...

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral ...

Genomic DNA of plants and bacteria that have acquired a transposable element, even if the latter was donated from a recombinant vector no longer present ... Oversight Review Form—For HIV Clinical ...

Immunizing the host with a piece of viral DNA rather than an antigenic protein fragment of the virus, helps to stimulate the generation of cell-mediated immunity (Fig. 2). DNA vaccines contain the ...